Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi
Companies, including start-ups, are usually focused solely on the development of the product and/or the technical platform in the early days. As understandable and important these aspects are, if they don’t start to think about their public communications strategy from the very beginning, they might be in danger of failing.
Already in the very early stages of the development of pharmaceuticals or med tech products, companies need to think about the following key points:
Will patients need and want the new product?
Will physicians prescribe it?
Will payers pay for it?
And thus they should come up with a convincing value story towards all stakeholders as only if they could convince all of these, investors will see the potential return of investment! But ultimately, all of that needs to be communicated… The reimbursement veteran Dr. Stefan Walzer these and more aspects around (global and local) communication with the communication expert Dr. Arne Näveke.
✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #medtech #pharmaceuticals #communications #funding #medicaldevices #germany
Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi
New methods such as diagnostics need to be assessed and the included in the reimbursement catalogue in the outpatient setting in Germany. However, key question remains which requirements are needed for such an evaluation and who is responsible for it. In some instances the responsible body is a sub-committee of the German federal Committee (G-BA) the so-called evaluation committee. But how does that body come to a conclusion and what do they really assess. How does price setting work in such an environment.
The reimbursement veteran Dr. Stefan Walzer discussed all of these questions and many more secrets with the Head of the arbitration board of the before-mentioned evaluation committee, Prof. Jürgen Wasem.
✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations
#pricing #medtech #diagnostics #arbitrationboard #funding #medicaldevices #germany
Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?
In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the invented approach by Dr. Kasia Hein-Peters is called DIVE. Within these approaches, all stakeholders would always need to be captured and dealt with - clinical development, regulatory and payers.
✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #innovation #pricing #drugs #medtech #livescience #strategy